AR042861A1 - Forma de presentacion para administracion por via oral, para ester etilico de acido 3-((2-((4-(hexiloxicarbonilamino-iminome-til)-fenilamino)-metil)-1-metil-1h-bencimipropionico y sus sales - Google Patents

Forma de presentacion para administracion por via oral, para ester etilico de acido 3-((2-((4-(hexiloxicarbonilamino-iminome-til)-fenilamino)-metil)-1-metil-1h-bencimipropionico y sus sales

Info

Publication number
AR042861A1
AR042861A1 ARP030100779A ARP030100779A AR042861A1 AR 042861 A1 AR042861 A1 AR 042861A1 AR P030100779 A ARP030100779 A AR P030100779A AR P030100779 A ARP030100779 A AR P030100779A AR 042861 A1 AR042861 A1 AR 042861A1
Authority
AR
Argentina
Prior art keywords
methyl
ethyl ester
possibly
pharmaceutically acceptable
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ARP030100779A
Other languages
English (en)
Inventor
Ulrich Brauns
Norbert Hauel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27789735&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR042861(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE10209985A external-priority patent/DE10209985A1/de
Priority claimed from DE2002145624 external-priority patent/DE10245624A1/de
Application filed by Boehringer Ingelheim Pharma GmbH Co KG filed Critical Boehringer Ingelheim Pharma GmbH Co KG
Publication of AR042861A1 publication Critical patent/AR042861A1/es
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Presentación para administración por vía oral, para la sustancia activa éster etílico de ácido 3-[(2-{[4-(hexiloxi-carbonilamino-imino-metil)-fenilamino]-metil}-1-metil-1H-bencimidazol-5-carbonil)-piridin-2-il-amino]-propiónico y sus sales farmacológicamente tolerables. Reivindicación 1: Composición farmacéutica para administración por vía oral, que comprende al menos: a) éster etílico de ácido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}-1-metil-1H-bencimidazol-5-carbonil)-piridin-2-il-amino]-propiónico o una de sus sales farmacéuticamente aceptables, y b) uno o varios ácidos orgánicos farmacéuticamente aceptables, con una solubilidad en agua > 1 g/250 ml. a 20° C. Reivindicación 14: Procedimiento para preparar una composición farmacéutica para administración por vía oral que contiene éster etílico de ácido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}-1-metil-1H-bencimidazol-5-carbonil)-piridin-2-il-amino]-propiónico o una de sus sales fisiológicamente tolerables, que comprende los pasos de: a) elaborar el material del núcleo a partir de uno o varios ácidos orgánicos farmacéuticamente aceptables con una solubilidad en agua > 1 g/250 ml. a 20° C, eventualmente con adición de agentes aglutinantes u otras sustancias auxiliares tecnológicas, en procedimientos en bombo, en discos granuladores, o por medio de extrusión/esferonización, b) aplicar una capa aislante compuesta por uno o varios polímeros solubles en agua, farmacéuticamente aceptables, eventualmente con adición de plastificantes, agentes disgregantes y/o pigmentos sobre el material del núcleo, c) aplicar la sustancia activa desde una dispersión que contiene agente aglutinante y eventualmente agente disgregante, y secar simultánea y/o ulteriormente, para eliminar el agente dispersante, d) eventualmente aplicar un revestimiento a base de formadores de película, plastificante y eventualmente pigmentos, y e) llenar los gránulos así obtenidos, que contienen sustancia activa, en cápsulas duras.
ARP030100779A 2002-03-07 2003-03-07 Forma de presentacion para administracion por via oral, para ester etilico de acido 3-((2-((4-(hexiloxicarbonilamino-iminome-til)-fenilamino)-metil)-1-metil-1h-bencimipropionico y sus sales Pending AR042861A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10209985A DE10209985A1 (de) 2002-03-07 2002-03-07 Oral zu applizierende Darreichungsform für 3-[(2-{[4-(Hexyloxycarbonylaminoimino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propinsäure-ethylester und dessen Salze
DE2002145624 DE10245624A1 (de) 2002-09-30 2002-09-30 Oral zu applizierende Darreichungsform für 3-[(2-{[4-(Hexyloxycarbonylaminoimino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2yl-amino]-propinsäure-ethylester und dessen Salze

Publications (1)

Publication Number Publication Date
AR042861A1 true AR042861A1 (es) 2005-07-06

Family

ID=27789735

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP030100779A Pending AR042861A1 (es) 2002-03-07 2003-03-07 Forma de presentacion para administracion por via oral, para ester etilico de acido 3-((2-((4-(hexiloxicarbonilamino-iminome-til)-fenilamino)-metil)-1-metil-1h-bencimipropionico y sus sales
ARP090102391A Pending AR072385A2 (es) 2002-03-07 2009-06-26 Metanosulfonato de ester etilico de acido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}-1-metil-1h-bencimidazol-5-carbonil)-piridin-2-il-amino]-propionico y composicion farmaceutica para administracion por via oral que lo contiene

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP090102391A Pending AR072385A2 (es) 2002-03-07 2009-06-26 Metanosulfonato de ester etilico de acido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}-1-metil-1h-bencimidazol-5-carbonil)-piridin-2-il-amino]-propionico y composicion farmaceutica para administracion por via oral que lo contiene

Country Status (36)

Country Link
US (2) US20190231766A1 (es)
EP (2) EP1870100B1 (es)
JP (3) JP3866715B2 (es)
KR (1) KR101005716B1 (es)
CN (1) CN100528157C (es)
AR (2) AR042861A1 (es)
AT (1) ATE540943T1 (es)
AU (1) AU2003210400B8 (es)
BR (1) BRPI0306559B8 (es)
CA (1) CA2476054C (es)
CL (1) CL2009001915A1 (es)
CO (1) CO5611149A2 (es)
CY (4) CY1112796T1 (es)
DE (1) DE122012000047I1 (es)
DK (2) DK1870100T3 (es)
EA (1) EA009664B1 (es)
EC (1) ECSP045331A (es)
ES (2) ES2380704T3 (es)
HK (1) HK1078792A1 (es)
HR (1) HRP20040807B1 (es)
IL (3) IL163863A0 (es)
LU (2) LU92025I2 (es)
ME (1) ME00325B (es)
MX (1) MXPA04008542A (es)
MY (1) MY143734A (es)
NO (3) NO326918B1 (es)
NZ (2) NZ546367A (es)
PE (1) PE20030889A1 (es)
PL (2) PL210862B1 (es)
PT (2) PT1485094E (es)
RS (1) RS52088B (es)
SG (1) SG146435A1 (es)
SI (2) SI1870100T1 (es)
TW (1) TWI293879B (es)
WO (1) WO2003074056A1 (es)
ZA (1) ZA200406071B (es)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
US20050070537A1 (en) 2002-10-10 2005-03-31 Chris Rundfeldt Use of dihydroimidazolones for the treatment of dogs
DE10337697A1 (de) * 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
DE10339862A1 (de) * 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
DE10341043A1 (de) * 2003-09-03 2005-03-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue oral zu applizierende Darreichungsform für 3-[(2-{[4-Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester und dessen Salze
WO2005113010A1 (ja) * 2004-05-24 2005-12-01 Qualicaps Co., Ltd. 表面改質および溶解性が改善された硬カプセル
DE102004062864A1 (de) 2004-12-21 2006-06-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Folienbehälter
US20060222640A1 (en) * 2005-03-29 2006-10-05 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for treatment of thrombosis
DE102005025728A1 (de) 2005-06-04 2006-12-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-Propionsäure-ethylester
DE102005061623A1 (de) * 2005-12-21 2007-06-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verbessertes Verfahren zur Herstellung von 4-(Benzimidazolylmethylamino)-Benzamidinen und deren Salzen
DE102005061624A1 (de) * 2005-12-21 2007-06-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verbessertes Verfahren zur Herstellung von Salzen von 4-(Benzimidazolylmethylamino)-Benzamidinen
CA2657266A1 (en) * 2006-07-17 2008-01-24 Boehringer Ingelheim International Gmbh New indications for direct thrombin inhibitors in the cardiovascular field
EP2043691A1 (en) * 2006-07-17 2009-04-08 Boehringer Ingelheim International GmbH New paediatric indications for direct thrombin inhibitors
US20100087488A1 (en) * 2006-10-10 2010-04-08 Boehringer Ingelheim International Gmgh Physiologically Acceptable Salts of 3-[(2--1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester
CA2716642C (en) * 2008-03-28 2017-02-28 Boehringer Ingelheim International Gmbh Method for manufacturing acid pellets
NZ586868A (en) * 2008-03-28 2012-02-24 Boehringer Ingelheim Int Process for preparing orally administered dabigatran formulations
CN102099012A (zh) * 2008-07-14 2011-06-15 贝林格尔.英格海姆国际有限公司 制备含有达比加群的药物制剂的方法
EP2564833B1 (en) 2008-07-28 2017-12-20 Takeda Pharmaceutical Company Limited Photostabilized pharmaceutical composition
EP2328580A1 (en) * 2008-08-19 2011-06-08 Boehringer Ingelheim International GmbH Dabigatran for percutaneous interventional cardiac catheterisation
EP2328581A1 (en) * 2008-08-19 2011-06-08 Boehringer Ingelheim International GmbH Use of dabigatranetexilate for treating patients with pulmonary hypertension
US20120142703A1 (en) 2009-05-14 2012-06-07 Boehringer Ingelheim International Gmbh New combination therapy in treatment of oncological and fibrotic diseases
JP2013502449A (ja) 2009-08-24 2013-01-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ダビガトランエテキシレート過剰投与による活性炭の緊急処置
DK2542224T3 (da) 2010-03-01 2014-10-20 Ratiopharm Gmbh Oral farmaceutisk sammensætning indeholdende dabigatranetexilat
US20130149346A1 (en) 2010-03-08 2013-06-13 ratiopharm GmbH Graf-Arco-Strasse 3 Dabigatran etexilate-containing pharmaceutical composition
US20130177652A1 (en) 2010-07-01 2013-07-11 Krka, Tovarna Zdravil, D.D., Novo Mesto Pharmaceutical oral dosage forms comprising dabigatran etexilate and its pharmaceutically acceptable salts
CN103025715A (zh) 2010-07-09 2013-04-03 埃斯特维化学股份有限公司 用于制备凝血酶特异性抑制剂的中间体和方法
EP2937343A1 (en) 2010-07-09 2015-10-28 Esteve Química, S.A. Process of preparing a thrombin specific inhibitor
EP2603503B1 (en) 2010-09-27 2015-08-05 ratiopharm GmbH Dabigatran etexilate bismesylate salt, solid state forms and process for preparation thereof
WO2012162492A1 (en) * 2011-05-24 2012-11-29 Teva Pharmaceutical Industries Ltd. Compressed core comprising organic acids for a pharmaceutical composition
CN102391250B (zh) * 2011-08-29 2013-06-19 石药集团欧意药业有限公司 一种达比加群酯化合物、制备方法及其药物组合物
AU2012357956A1 (en) 2011-12-22 2014-05-22 Boehringer Ingelheim International Gmbh Immediate release multi unit pellet system
US9212166B2 (en) 2012-01-20 2015-12-15 Cadila Healthcare Limited Process for the preparation of dabigatran etexilate mesylate and polymorphs of intermediates thereof
EP2806858A1 (en) 2012-01-24 2014-12-03 Boehringer Ingelheim International Gmbh Novel orally administered dabigatran formulation
PT2817000T (pt) * 2012-02-21 2021-11-02 Towa Pharmaceutical Europe S L Composições farmacêuticas de dabigatrano etexilato
EP2631234A1 (en) 2012-02-23 2013-08-28 Esteve Química, S.A. Solid forms of dabigatran etexilate mesylate and processes for their preparation
WO2013144971A1 (en) 2012-03-27 2013-10-03 Cadila Healthcare Limited New solid forms of dabigatran etexilate bisulfate and mesylate and processes to prepare them
US9273030B2 (en) 2012-04-02 2016-03-01 Msn Laboratories Private Limited Process for the preparation of benzimidazole derivatives and salts thereof
WO2014001220A1 (en) 2012-06-25 2014-01-03 Boehringer Ingelheim International Gmbh Method for prevention of stroke
US20150225370A1 (en) 2012-09-28 2015-08-13 Ranbaxy Laboratories Limited Process for the preparation of dabigatran etexilate or pharmaceutically acceptable salt thereof
IN2015DN02616A (es) 2012-09-28 2015-09-18 Ranbaxy Lab Ltd
EP2722033A1 (en) 2012-10-19 2014-04-23 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical Compositions of Dabigatran Free Base
WO2014060561A1 (en) 2012-10-19 2014-04-24 Sanovel Ilac Sanayi Ve Ticaret A.S. Oral pharmaceutical formulations comprising dabigatran
EP2740471B1 (en) * 2012-12-07 2015-05-27 Hexal AG Oral pharmaceutical composition comprising dabigatran etexilate
CN103127109B (zh) * 2013-02-05 2014-08-13 南京华威医药科技开发有限公司 含达比加群酯或其盐和水合物的药用组合
EP2835370A1 (en) 2013-08-08 2015-02-11 Medichem, S.A. New crystals of dabigatran etexilate mesylate
CN104414995A (zh) * 2013-09-04 2015-03-18 天津汉瑞药业有限公司 甲磺酸达比加群酯的药用组合物
EP2853260A1 (en) 2013-09-27 2015-04-01 ratiopharm GmbH Pharmaceutical preparation comprising dabigatran etexilate bismesylate
US9820988B2 (en) 2014-03-24 2017-11-21 Boehringer Ingelheim Vetmedica Gmbh Treatment of epileptic disorders in feline animals
WO2015145462A1 (en) 2014-03-26 2015-10-01 Cadila Healthcare Limited Pharmaceutical compositions of dabigatran
EP2929884A1 (en) 2014-04-11 2015-10-14 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical combinations of dabigatran and h2-receptor antagonists
US10130618B2 (en) 2014-04-11 2018-11-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical combinations of dabigatran and proton pump inhibitors
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
CA3001495C (en) * 2014-11-03 2021-07-20 Solipharma Llc Formulations of dabigatran etexilate or dabigatran etexilate salts and preparation methods thereof
CN105640909B (zh) 2014-11-14 2019-09-20 正大天晴药业集团股份有限公司 一种含有达比加群酯的药用组合物
WO2016107605A1 (zh) 2014-12-31 2016-07-07 昆明积大制药股份有限公司 药物组合物及其制备方法
CN106924256B (zh) * 2015-12-25 2022-08-19 深圳市药欣生物科技有限公司 药物组合物及其制备方法
CN105797162B (zh) * 2014-12-31 2022-10-25 昆明积大制药股份有限公司 药用辅料表面改性方法
TR201502223A2 (tr) 2015-02-25 2016-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dronedaron ve dabigatranın farmasötik kombinasyonları.
CN106999434B (zh) * 2015-04-08 2020-05-22 杭州领业医药科技有限公司 一种含半胱氨酸盐酸盐的微丸及其制备方法
WO2017013106A1 (en) 2015-07-20 2017-01-26 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical formulations of dabigatran free base
CN105919962B (zh) * 2015-12-18 2019-01-18 重庆两江药物研发中心有限公司 一种达比加群酯片剂及其制备方法
WO2017111637A1 (en) 2015-12-23 2017-06-29 Zaklady Farmaceutyczne Polpharma Sa Pharmaceutical composition comprising dabigatran or a pharmaceutically acceptable salt thereof
EP3184102A1 (en) 2015-12-23 2017-06-28 Hexal AG Pharmaceutical composition of vortioxetine hydrobromide comprising an inert core formed of an acidic reacting compound
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
TR201606697A2 (tr) 2016-05-20 2017-12-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dabi̇gatranin yeni̇ oral farmasöti̇k formülasyonlari
EP3332771A1 (en) 2016-12-07 2018-06-13 Sanovel Ilac Sanayi ve Ticaret A.S. Multilayered tablet compositions of dabigatran
TR201617984A2 (tr) 2016-12-07 2018-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dabi̇gatranin farmasöti̇k kompozi̇syonlari
EP3342401A1 (en) 2016-12-28 2018-07-04 Sanovel Ilac Sanayi ve Ticaret A.S. Bilayer tablet formulations of dabigatran etexilate
JP2018184375A (ja) 2017-04-27 2018-11-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ダビガトランエテキシラート又は医薬的に許容されるその塩を含む錠剤及びその製造方法
WO2018229784A1 (en) * 2017-06-14 2018-12-20 Natco Pharma Limited Pharmaceutical compositions of dabigatran
CN109125274A (zh) * 2017-06-28 2019-01-04 上海美悦生物科技发展有限公司 注射用苯并咪唑类药用酸组合物及其制备方法和用途
TR201722186A2 (tr) 2017-12-27 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dabi̇gatranin farmasöti̇k kompozi̇syonlari
TR201722353A2 (tr) 2017-12-27 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dabi̇gatran eteksi̇lat i̇çeren oral uygulama i̇çi̇n farmasöti̇k formülasyon
TR201722323A2 (tr) 2017-12-27 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dabi̇gatranin oral farmasöti̇k kompozi̇syonlari
TR201722630A2 (es) * 2017-12-28 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
CN110339193B (zh) 2018-04-04 2022-04-29 上海汉都医药科技有限公司 含达比加群酯的药物组合物及其制备方法
KR20200082641A (ko) 2018-12-31 2020-07-08 주식회사 유영제약 다비가트란 에텍실레이트를 포함하는 약제학적 조성물
EP3771465A1 (en) 2019-08-01 2021-02-03 Zaklady Farmaceutyczne Polpharma SA Pharmaceutical composition comprising dabigatran etexilate
KR20210157693A (ko) 2020-06-22 2021-12-29 한국유나이티드제약 주식회사 다비가트란 에텍실레이트를 포함하는 경구용 약학조성물
KR20210157692A (ko) 2020-06-22 2021-12-29 한국유나이티드제약 주식회사 다비가트란 에텍실레이트를 포함하는 경구용 약학조성물
KR20210157691A (ko) 2020-06-22 2021-12-29 한국유나이티드제약 주식회사 다비가트란 에텍실레이트를 포함하는 경구용 약학조성물
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide
CN115227663B (zh) * 2021-04-22 2023-12-12 石药集团恩必普药业有限公司 一种甲磺酸达比加群酯胶囊及其制备方法
WO2023139243A1 (en) 2022-01-21 2023-07-27 Adamed Pharma S.A A process for preparation of tartaric acid cores for dabigatran pellets and the pellets containing dabigatran
GR1010399B (el) * 2022-04-05 2023-02-03 Φαρματεν Α.Β.Ε.Ε., Φαρμακευτικο σκευασμα που περιλαμβανει εναν αντιπηκτικο παραγοντα και μεθοδος παραγωγης αυτου
WO2024175037A1 (zh) * 2023-02-21 2024-08-29 广州玻思韬控释药业有限公司 达比加群酯或其药物可接受的盐的微丸

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) * 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
DE3126703A1 (de) * 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
JPS58134033A (ja) * 1982-02-02 1983-08-10 Fujisawa Pharmaceut Co Ltd 医薬組成物
PE121699A1 (es) * 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
DE10133786A1 (de) * 2001-07-16 2003-02-06 Boehringer Ingelheim Pharma Verwendung von Thrombin-Inhibitoren zur Behandlung von Arthritis

Also Published As

Publication number Publication date
JP4953727B2 (ja) 2012-06-13
ATE540943T1 (de) 2012-01-15
BRPI0306559B1 (pt) 2021-05-18
PT1870100E (pt) 2012-04-17
EP1485094A1 (de) 2004-12-15
NO2013001I2 (no) 2014-09-01
US20200085807A1 (en) 2020-03-19
IL209368A (en) 2012-10-31
AR072385A2 (es) 2010-08-25
CY2012031I2 (el) 2015-08-05
CO5611149A2 (es) 2006-02-28
CY2012020I2 (el) 2015-08-05
EP1485094B1 (de) 2012-07-04
MY143734A (en) 2011-07-15
CN1638771A (zh) 2005-07-13
MXPA04008542A (es) 2004-12-06
NO326918B1 (no) 2009-03-16
HRP20040807B1 (hr) 2014-11-21
ES2390661T5 (es) 2020-12-04
KR101005716B1 (ko) 2011-01-05
DK1485094T3 (da) 2012-10-15
DE122012000047I1 (de) 2012-09-13
PL394601A1 (pl) 2011-07-18
ES2380704T9 (es) 2013-07-24
CY2012020I1 (el) 2015-08-05
EP1485094B2 (de) 2020-03-25
TWI293879B (en) 2008-03-01
CY1112796T1 (el) 2015-08-05
CL2009001915A1 (es) 2010-02-12
ES2390661T3 (es) 2012-11-15
EA200401136A1 (ru) 2005-04-28
CY2012031I1 (el) 2015-08-05
BRPI0306559B8 (pt) 2021-05-25
IL209368A0 (en) 2011-01-31
PL210862B1 (pl) 2012-03-30
JP2006328081A (ja) 2006-12-07
NZ546367A (en) 2008-08-29
EP1870100A1 (de) 2007-12-26
CN100528157C (zh) 2009-08-19
HRP20040807A2 (en) 2005-02-28
DK1870100T3 (da) 2012-05-14
HK1078792A1 (en) 2006-03-24
IL163863A (en) 2013-02-28
JP2007056018A (ja) 2007-03-08
WO2003074056A1 (de) 2003-09-12
IL163863A0 (en) 2005-12-18
PT1485094E (pt) 2012-10-09
KR20040099298A (ko) 2004-11-26
PL212566B1 (pl) 2012-10-31
NO2013001I1 (no) 2013-02-11
TW200306188A (en) 2003-11-16
NO332209B1 (no) 2012-07-30
ES2380704T3 (es) 2012-05-17
EP1870100B1 (de) 2012-01-11
SI1870100T1 (sl) 2012-05-31
ME00325B (me) 2011-05-10
US20190231766A1 (en) 2019-08-01
MEP50708A (en) 2011-02-10
DK1485094T4 (da) 2020-06-22
JP3866715B2 (ja) 2007-01-10
NZ535663A (en) 2006-06-30
RS52088B (sr) 2012-06-30
AU2003210400A1 (en) 2003-09-16
BR0306559A (pt) 2004-11-30
SG146435A1 (en) 2008-10-30
RS79204A (en) 2007-02-05
AU2003210400B2 (en) 2008-08-07
LU92117I2 (fr) 2013-02-19
CA2476054C (en) 2011-11-08
SI1485094T1 (sl) 2012-10-30
PL370517A1 (en) 2005-05-30
PE20030889A1 (es) 2003-12-10
SI1485094T2 (sl) 2020-08-31
NO20042361D0 (no) 2004-06-07
JP2005519099A (ja) 2005-06-30
ECSP045331A (es) 2006-04-19
CY1113158T1 (el) 2015-08-05
EA009664B1 (ru) 2008-02-28
AU2003210400B8 (en) 2008-09-25
NO20042361L (no) 2004-06-07
ZA200406071B (en) 2005-11-30
CA2476054A1 (en) 2003-09-12
LU92025I2 (fr) 2012-08-20
NO20081304L (no) 2004-06-07

Similar Documents

Publication Publication Date Title
AR042861A1 (es) Forma de presentacion para administracion por via oral, para ester etilico de acido 3-((2-((4-(hexiloxicarbonilamino-iminome-til)-fenilamino)-metil)-1-metil-1h-bencimipropionico y sus sales
ES2249849T3 (es) Forma de administracion oral que comprende un inhibidor de la bomba de protones (por ejemplo pantoprazol).
ES2543427T3 (es) Forma farmacéutica oral de deferasirox
ES2256943T3 (es) Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
TWI345466B (en) Crystalline forms
Abruzzo et al. Bilayered buccal films as child-appropriate dosage form for systemic administration of propranolol
US9011926B2 (en) Method for producing granules
JP4749660B2 (ja) 安定な固形製剤
AR100473A2 (es) Un método para la manufactura de una preparación para administración oral
US20140205670A1 (en) Stable solid preparations
CN102316730A (zh) 用于减轻全身性炎症和/或血管炎症的n-乙酰半胱氨酸(nac)的控释
US20040157928A1 (en) Solvent system of hardly soluble drug with improved dissolution rate
RU2452469C2 (ru) Составы бензимидазолилпиридилэфиров
KR20090080037A (ko) 점막 비점착성 필름 제형
US20090318558A1 (en) Solvent system of hardly soluble drug with improved dissolution rate
AR012698A1 (es) Formulacion farmaceutica de omeprazol
BRPI0712353B1 (pt) comprimidos sublinguais de analgésicos de opióide de dose baixa e processo de preparação
JP2008514637A (ja) Ｃｒｔｈ２、ｃｏｘ−２およびｆａａｈのモジュレーター
CN107266433A (zh) sGC刺激剂
BRPI0717570B1 (pt) composição farmacêutica sólida adequada para administração oral, seu uso e seu processo de produção
RU2009123370A (ru) Трансдермальная терапевтическая система с высоким уровнем использования активного вещества и точностью дозирования
ATE457719T2 (de) Pharmazeutische zusammensetzungen mit kontrollierter freisetzung für säurelabile arzneimittel
WO2006066932A1 (en) Stable pharmaceutical composition comprising an active substance in the form of solid solution
JP2005533751A5 (es)
CN111012756A (zh) 一种达比加群酯药物组合物及其制备方法

Legal Events

Date Code Title Description
FG Grant, registration